biotech firesales Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : biotech firesales

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: tuck	2/21/2017 9:08:35 AM
	Read Replies (1) of 3661

Trevena (TRVN) off 34% premarket. They needed a home run in P3 post op pain trials and got a triple. Hit primary endpoints, but weren't stat sig on certain safety related secondary ones at all doses (only the lowest dose). Throws label/marketability in doubt. The PR doesn't give the data for the higher dose safety measures, so one can't discern the strength of the trend towards stat sig (company says the complete data being held for medical meeting). If they got close, might be enough. If not, cost/benefit versus morphine will be a tough sell. Had a modest position in this one ( less modest in charity portfolio, oh well) and will hold for the moment, but not recommending anything here on these equivocal results, as it's the only program the company has that matters. Cheers, Tuck

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next